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Autophagy is a protein degradative process important for normal cellular metabolism. It is apparently used also by
cells to eliminate invading pathogens. Interestingly, many pathogens have learned to subvert the cell’s autophagic
process. Here, we review the interactions between viruses and cells in regards to cellular autophagy. Using findings
from hepatitis B virus and human retroviruses, HIV-1 and HTLV-1, we discuss mechanisms used by viruses to usurp
cellular autophagy in ways that benefit viral replication.Review
Background
The term “autophagy” means “self-eating” derived from
Greek. It was first mentioned by Christian De Duve in
1963 [1], and has been used since to describe a bulk deg-
radation process by lysosome-dependent mechanism.
Autophagy functions to degrade protein aggregates, main-
tain the homeostasis of organelles, such as mitochondria,
peroxisomes and ribosomes, and destroy intracellular
pathogens [2]. The selectivity of autophagic degradation is
thought to be achieved by recognizing post-modification
such as ubiquitination [3] or acetylation on proteins [4,5].
Several autophagy receptors or adaptors, including
SQSTM1/p62, NBR1 and HDAC6, have been identified,
and they are considered to function by recognizing and
recruiting ubiquitinated protein aggregates to be degraded
through the autophagy pathway [6]. Until now, several
types of autophagy-mediated degradation have been
described. These include: 1) macroautophagy that is used
to sequester cytoplasmic materials such as organelles and
intracellular pathogens by de novo formation of double-
layer membranes [7]: 2) microautophagy that is used to
engulf a part of the cytoplasm by the invagination of
lysosomal membrane into lysosome lumen [8]; 3)
chaperone-mediated autophagy that is used to transport
specific cytosolic proteins by chaperones to lysosomal* Correspondence: kjeang@nih.gov; cneuveut@pasteur.fr
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reproduction in any medium, provided the ordegradation [9]. Macroautophagy will be discussed in this
review and is herein referred to as autophagy.The autophagy machinery
The autophagy machinery contains more than 30
autophagy-related (Atg) genes; most of which are highly
conserved from yeast to mammal. When autophagy is
induced by stressed conditions such as starvation, the
first step is the nucleation of phagophore membranes
(Figure 1), also called pre-autophagosomal structures
[10] or isolation membrane, which likely originates from
the endoplasmic reticulum, Golgi complex, mitochon-
dria, endosomes and/or the plasma membrane [11]. In
nutrient rich condition, the mammalian target of rapa-
mycin (mTORC1) kinase is activated by class I PI3K and
amino acids to inhibit the autophagy pathway by
associating with and inactivating the ULK1/2 (Atg1 in
yeast) complex (including ULK1/2, Atg13 and FIP200),
which is essential for the induction of autophagy [12-14]
(Figure 1). Under growth factor deprivation or nutrient
starvation, the activity of mTORC1 is inhibited by en-
ergy sensor AMP activated protein kinase (AMPK). The
ULK1/2 complex is also directly activated by AMPK-
mediated phosphorylation, resulting in the translocation
of ULK1/2 complex to the membrane of endoplasmic
reticulum [14-17]. The ULK1/2 complex works mechanis-
tically, likely through the recruitment of the Vps34 (class
III PI3K)-Beclin-1 complex to the site of autophagosome
generation to produce phosphatidylinositol-3-phosphate
(PI3P), which is enriched on the inner surfaces of the pha-
gophores, and to recruit PI3P binding proteins includingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 A schematic summary of the autophagy machinery. (1) The nucleation of phagophore membranes (pre-autophagosomal structures
or isolation membrane): In nutrient rich condition, the mTORC1 kinase associates with the ULK1/2 complex to inhibit the initiation of autophagy.
Under growth factor deprivation or nutrient starvation, energy sensor AMPK suppresses the activity of mTORC1 and activates the ULK1/2 complex
which is essential for the induction of autophagy. The ULK1/2 complex likely recruits the Vps34-Beclin-1 complex to the site of autophagosome
generation. (2) The formation of autophagosomes: Two ubiquitin-like proteins, Atg12 and LC3, are involved in the formation of enclosed double-
membrane vesicles (autophagosomes) in order to sequester cytoplasmic material. Atg12 is conjugated with Atg5 by Atg7 (E1-like ubiquitin
activating enzyme) and Atg10 (E2-like ubiquitin conjugating enzyme), which then form a complex with Atg16L1; this complex (E3-like ubiquitin
ligase) works with Atg7 (E1) and Atg3 (E2) to conjugate LC3-I with phosphatidylethanolamine (PE), to create a form termed LC3-II, which is
specifically located on autophagosome structures. (3) The maturation of autophagosomes: Autophagosomes are sequentially fused with
endosomes and lysosomes to form autolysosomes. The lysosomal hydrolases degrade eventually the content of autophagosomes. To date,
Vps34-Beclin-1 complex, UVRAG, SNARE, ESCRT-III, Rab7, HSP70 and TECPR1 have been identified to be involved in autophagosome-lysosome
fusion. Rubicon protein may serve as a suppressor of autophagosome maturation by interacting with VPS34-Beclin-1 complex.
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for autophagy initiation [13,18-22] (Figure 1).
After phagophore membrane formation, the phagophores
are elongated by two ubiquitin-like proteins, Atg12 and
microtubule-associated protein 1 light chain 3 (LC3, Atg8
in yeast), to form enclosed double-membrane vesicles as
known as autophagosomes in order to sequester a part of
the cytoplasm (Figure 1). In this process, Atg12 is first acti-
vated by E1-like ubiquitin activating enzyme Atg7, trans-
ferred to E2-like ubiquitin conjugating enzyme Atg10, and
then conjugated to a lysine residue (K130) of Atg5 [23].
The covalently linked Atg12-Atg5 and another membrane-
bound factor, Atg16L1, further form a complex, which
functions to expand the phagophore membrane; this com-
plex dissociates from the membrane when autophagosomes
are formed [24-26]. In a second step, full-length LC3 precur-
sor is translated and immediately cleaved by the protease
Atg4B to produce LC3-I (cytosolic form) with a free gly-
cine residue [27,28]. Upon autophagy induction, LC3-I is
conjugated to phosphatidylethanolamine [10] by thefunctions of E1-like ubiquitin activating enzyme Atg7 and
another E2-like ubiquitin conjugating enzyme Atg3 to
produce LC3-II [29-31]. The Atg12-Atg5-Atg16L1 com-
plex has been reported to guide LC3-I to the phagophore
membrane, and to function as E3-like ubiquitin ligase to
promote the lipidation of LC3-I by PE [32,33]. LC3-II is
specifically located on autophagosome structures, making
it a commonly used specific marker for identifying autop-
hagosomes [10]. LC3-II, which is located on inner mem-
brane of autophagosomes, is eventually degraded after the
fusion of the autophagosome with lysosome; however, the
LC3-II protein on the outer membrane can be recycled
and reused after delipidation by Atg4 [28].
A maturation step of autophagy is the sequential fusion
of autophagosomes with endosomes and lysosomes to
form autolysosomes; this fusion leads to the eventual
degradation of the content of autophagosomes [34,35]
(Figure 1). Recent reports suggested that SNARE [36],
ESCRT-III [37], small GTPase Rab7 [38,39], and HSP70
[40,41] are involved in autophagosome maturation. Other
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to interact with Vps34-Beclin-1 complex to activate
GTPase Rab7 and autophagosome-lysosome fusion [42]
and that the Rubicon protein suppresses the maturation of
autophagosomes by interacting VPS34-Beclin-1 complex
[43]. The latter observation indicates that the VPS34-
Beclin-1 complex can also regulate autophagosome
maturation depending on selective protein association.
Additionally, the TECPR1 protein is thought to form a
complex with Atg12-Atg5 and PI3P to enhance the fusion
of autophagosomes with lysosomes [44]. At the same time,
it should be noted that functional lysosomes are also
needed for autophagosome maturation. Thus, a deficiency
of Lamp2, which is an essential constituent of the lyso-
somal membrane, causes autophagosome accumulation
and disrupts proper autophagy-mediated degradation [45].
Moreover, the disruption of lysosomal acidification by
bafilomycin A (BFA, an inhibitor of the lysosomal vacuolar-
ATPase) or chloroquine (a lysosomotrophic agent to
increase pH in lysosomes) strongly impairs autophago-
some-lysosome fusion [46,47]. The mechanism of how lyso-
somal acidification influences autophagosome-lysosome
fusion, however, needs further exploration.
Diseases associated with the mutation of autophagy-related
genes
Genetic mutations of several autophagy-related genes
have been linked to human diseases. For example,
Beclin-1 has been suggested to suppress tumorigenesis
and progression of breast cancer [48]. The monoallelic
deletion of Beclin-1 has been observed in 40-75% of
human breast, ovarian, and prostate malignancies [49].
UVRAG is found to be monoallelically mutated in
human colon cancer, and UVRAG has been suggested to
act by inhibiting the proliferation and tumorigenic
activity of human colon cancer cells [50,51]. By
Genome-Wide Association Study (GWAS), IRGM1
(autophagy-stimulatory immunity-related GTPase) and
Atg16L1 have been identified to be associated with the
pathogenesis of chronic inflammatory bowel diseases,
such as Crohn’s disease [48,52]. The somatic mutation
of LAMP-2 has been linked to Danon disease, which
exhibits cardiac hypertrophy and the accumulation of
autophagosomes and lysosomal glycogen in cardiac
muscle cells causing clinical symptoms of cardiomyopa-
thy, myopathy and mental retardation [53,54]. The defi-
ciency of LAMP-2 in mice also results in similar
vacuolar cardioskeletal myopathy [53]. SQSTM1/p62 is
an autophagy receptor, which recognizes and sends ubi-
quitinated substrates to be degraded by autophagy.
Mutations in the ubiquitin associated (UBA) domain of
SQSTM1/p62 have been reported to be associated with
about 30% of Paget’s bone disease, which has disordered
NF-κB-dependent osteoclast function and is characterizedby focally increased and disorganized bone remodeling
[55]. These collective examples raise the notion that per-
turbed activity of the autophagy pathway influences geno-
mic instability and normal cellular metabolism [52].
Autophagy and cancer
The link between autophagy and cancer development has
been broadly established. Autophagy can clear toxic aggre-
gates and damaged mitochondria which may produce re-
active oxygen species (ROS) that cause DNA damage
[56,57], and autophagy has attributed roles in chromo-
some instability, including aneuploidy and gene amplifica-
tion [58-60]. Moreover, a deficiency of autophagy results
in failed degradation of SQSTM/p62, which plays a role in
activation of NF-κB and inflammation-mediated tumori-
genesis [56,61,62]. Thus, conceptually, autophagy serves
to reduce environmental insults and neutralize events that
favor cellular transformation. Indeed, in cellular trans-
formation, it has been commonly regarded that apoptosis
provides a protective mechanism in inciting the death of
aberrantly transformed cells. In that context, it is in-
creasingly recognized that apoptotic cell death of abnor-
mal cells can be complemented by apoptosis-independent
autophagy-dependent cell death [61,63], especially in the
elimination of transformed cells.
In a related aspect, the function of autophagy as a pro-
vider of nutrient and energy also contributes to tumor
survival, especially under metabolically stressful condi-
tion such as nutrient starvation and hypoxia [64]. This
concept is supported by the clinical observation that
biallelic loss of Beclin-1 has not been seen in cancer
patients [49,65], and by in vitro experiments showing
that autophagy deficiency achieved by small interfering
RNA targeting Beclin-1 or Atg5 reduces cellular proli-
feration and increases the death of cancer cells
[61,66,67]. Additionally, activation of autophagy is
observed within cancer cells treated with chemotherapy
or radiotherapy. Thus although these cancer therapies
are designed to kill most cancer cells, it is a concern that
by triggering increased autophagy they incite a reactive
response that helps the residual cancer cells survive and
resist extreme stress [64]. It is thus reasonable to consider
a cancer treatment approach that combines traditional
anti-cancer chemotherapy with autophagy inhibitors such
as hydroxychloroquine. Several clinical trials are underway
examining the effect of autophagy inhibitors on increasing
the sensitivity of cancers to chemotherapy [68,69].
Autophagy and pathogen clearance
Autophagy also functions as a cellular defense to remove
invading pathogens, in a process termed xenophagy; and
autophagy can serve to deliver antigen fragments of
pathogens for MHC class II presentation to activate the
adaptive immune system [70]. Many types of bacteria
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dation. For example, Mycobacterium tuberculosis can be
targeted by autophagy, and its clearance is enhanced by
cellular starvation and exposure to lipopolysaccharides.
The clearance of Toxoplasma gondii can be decreased
by treatment with Bafilomycin A (an autophagy inhibi-
tor) or Beclin-1 siRNA [71]. Ubiquitination of proteins is
likely a crucial step for the clearance of invading bac-
teria. NDP52 (nuclear dot protein 52kDa) functions
as an autophagy receptor that recognizes ubiquitinated
Salmonella enterica and captures it into autophago-
somes by interacting with LC3 [72]. Recently, Watson et
al. have observed that the cellular STING-dependent
pathway recognizes extracellular bacterial DNA, trigger-
ing the intracellular ubiquitination of bacterial proteins,
and that SQSTM/p62, NDP52 and the DNA-responsive
kinase TBK1 are used for autophagic degradation of bac-
teria [73]. However, it should be noted that many bac-
teria have evolved countermeasures to combat the cell’s
autophagic defense. For example, Legionella pneumo-
phila and Brucella abortus do induce cellular autophagy,
but can thwart the maturation step of autophagy
in order to facilitate pathogenic replication [70]. Simi-
larly, Mycobacterium tuberculosis can interfere with
autophagosome-lysosome fusion through its ESAT-6 Se-
cretion System-1 (ESX-1) [74].
Autophagy and viruses
Interestingly, most viruses, with a few exception such as
vesicular stomatitis virus (VSV), appear to have evolved
mechanisms to evade cellular clearance by autophagy
[75]. Many viruses have developed counteracting
mechanisms to escape autophagic degradation [66,76].
For instance, several herpesviruses, including herpes
simplex virus type 1 (HSV-1), bovine herpesvirus type 1
(BHV-1), human cytomegalovirus (HCMV), Kaposi’s
sarcoma-associated herpesvirus (KSHV), herpesvirus sai-
miri (HVS) and molluscum contagiosum virus (MCV),
can capably suppress autophagy. For HSV-1, the viral
protein ICP34.5 interacts with Beclin-1 to inhibit autop-
hagy induction [77,78].
Some DNA viruses including Epstein-Barr virus
(EBV), varicella-zoster virus (VZV), adenovirus, human
papillomavirus 16 (HPV16), simian virus 40 (SV40),
human parvovirus B19 (HPV-B19) and hepatitis B virus
(HBV), activate portions of the autophagy pathway and
employ this process to enhance viral replication. Thus,
autophagy-induced cell death assists the final step of the
adenovirus life cycle to release virus particles [79]. Many
RNA viruses, including VSV, coxsackievirus B4 (CVB4),
coxsackievirus B3 (CVB3), poliovirus, dengue virus-2
(DENV2), dengue virus-3 (DENV3), rotavirus, hepatitis
C virus (HCV), influenza virus A, have been observed to
induce autophagy, but inhibit autophagosome-lysosomefusion. [80]. For poliovirus and HCV, autophagy induc-
tion seems to provide cell membranes for RNA replica-
tion [81-84]. For influenza A virus, the viral M2 protein
inhibits autophagosome-lysosome fusion, possibly inhi-
biting MHC antigen presentation of influenza A virus
proteins to reduce host immune response [85]. Below,
we will discuss in greater depth lessons on autophagy
learned from hepatitis B virus and human retroviruses.
Lessons learned from HBV
The human hepatitis B virus (HBV) is the prototype
member of a family of small, enveloped DNA viruses
called Hepadnaviridae that infect a restricted number of
mammals and birds. Despite the existence of effective
vaccines, HBV remains one of the most significant
human pathogens with an estimated 2 billion people
infected worldwide, of whom 350 million are chronic
HBV carriers. Chronic hepatitis B is a major risk factor
for severe liver diseases including liver cirrhosis and
hepatocellular carcinoma (HCC). HCC is the fifth most
common cancer, and the third leading cause of cancer
death in the world [86].
Although chronic HBV infection has been epidemiolo-
gically linked to the development of HCC for more than
40 years, the mechanisms by which HBV infection
results in HCC are still unclear. The hepatitis B virus X
protein (HBx) has generally been viewed as an oncopro-
tein in viral carcinogenesis. In order to favor virus repli-
cation, HBx subverts cellular activities such as signal
transduction, transcription, autophagy, and proliferation.
In doing so, HBx apparently induces the accumulation
of cellular dysfunctions and damage, ultimately leading,
in the case of viral persistence, to cancer development.
HBV enhances and uses autophagy for its replication.
However, the mechanisms responsible for autophagy in-
duction as well as the step of HBV replication affected
by autophagy are still controversial [87,88]. Upon viral
infection, autophagy can be triggered by direct mecha-
nisms like the recognition of viral element that promote
autophagy protein expression, or by indirect mecha-
nisms like virus triggered cellular stress. For example,
during infection a large amount of viral proteins are
synthesized and unfolded, and the misfolded proteins
can activate ER stress response. HBV can use direct and
indirect mechanisms to induce autophagy (Figure 2).
Different groups have shown that HBV expression is
correlated with autophagy induction [87-89]. Two of
these publications observed that while HBV expression
induces the formation of early phagosomes, the rate of
autophagic protein degradation is seemingly not
increased [87,88,90]. These results argue that HBV acts
on the early step of phagosome formation. As noted
above, some viruses induce early steps in the autophagy
process, but delay phagosome maturation, in order to
Figure 2 Autophagy is induced by HBV expression and enhances HBV replication. HBV increases autophagy to favor its own replication.
The exact steps impacted by autophagy are still unclear, but it seems that autophagy can either enhance HBV DNA replication or favor HBV
envelopment. To date, different non-exclusive mechanisms for autophagy induction have been proposed. The regulatory protein HBx could
directly activate autophagy through the induction of PI3KC3 activity or the up-regulation of beclin1 expression. Finally the small envelope protein
(SHBs) has been shown to induce autophagy via the establishment of ER stress that triggers the unfolded protein response (UPR) and autophagy.
Interestingly, a study has reported that induction of UPR triggers autophagy-dependent degradation of three HBV envelope proteins. This
mechanism seems to be in contradiction with the previous finding. It will be interesting to determine if this autophagy-dependent mechanism
regulates the overall production of viral particles following autophagy induction.
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needed to determine carefully whether and how HBV
blocks the formation of late phagosomes. Interestingly,
Tang and collaborators have observed autophagy induc-
tion by HBV only under starvation condition. The dis-
crepancy between this work and other studies could
stem from the different cell lines used in these studies.
Alternatively the models used: transfected HBV genome
versus integrated HBV genome could lead to different
levels of viral protein expression, and increasing the level
of HBV protein can induce ER stress [93] thereby acti-
vating autophagy [94]. For future clarity, it will be neces-
sary to assess autophagy in the context of authentic
HBV infection.
The exact steps of HBV replication that are regulated
by autophagy remain to be identified. In extant publica-
tions the role of autophagy on the early steps of HBV in-
fection is not addressed; however, current data do
support that autophagy impacts late steps of HBV repli-
cation, increasing HBV production. Indeed, using either
an inhibitor of PI3KC3 or via the silencing of enzymes
essential for the formation of autophagosomes, Sir et al.showed that inhibition of autophagy had a marginal ef-
fect on HBV transcription and HBV RNA packaging, but
suppressed HBV DNA synthesis, suggesting an enhance-
ment of HBV DNA replication by autophagy [88]. They
further confirmed the role of autophagy in the production
of HBV virions in vivo using HBV transgenic mice with
liver-specific knockout of Atg5. They demonstrated in this
model that the formation of autophagosome is essential
for HBV DNA synthesis in the cytoplasm [90]. Again, in
this study the HBV DNA is integrated into the mouse
genome, preventing direct extrapolation of the findings to
in vivo HBV infection. Moreover, these studies are some-
what in contradiction with the study of Li and collabora-
tors who reported that the autophagy machinery is
needed for efficient envelopment of the nucleocapsids at
the ER membrane and has only a slight effect on HBV
DNA replication [87]. It is unclear the reasons for the dif-
ferences; in both studies, the HBV genome is transfected
into hepatoma cells, albeit using different techniques.
However, it may be that slight differences in the level of
viral protein expression and the cell lines employed could
account for the discrepancies between the two studies.
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remains a matter of discussion, the mechanisms leading
to the induction of autophagy by HBV remain also
unclear (Figure 2). It was first suggested that the viral
regulatory protein HBx was directly involved in
starvation-induced autophagy via the up–regulation of
Beclin-1 expression [89]. In that report, the authors
showed that HBx, a known weak transcriptional activa-
tor, transactivates the Beclin-1 promoter in hepatic and
hepatoma cell lines. They next demonstrated that silen-
cing of Beclin-1 expression by siRNA blocked the induc-
tion of autophagy by HBx, suggesting that HBx acts via
the transcriptional activation of Beclin-1. These authors,
however, did not include control experiments with a
transactivation-deficient HBx mutant and their siRNA
knock down results do not formally address increased
Beclin-1 transcription by HBx, rather the findings solely
indicate that Beclin-1 is essential for induction of
autophagy by HBx. This is an important point because
in another publication, Sir et al. did not observe induc-
tion of Beclin-1 expression by either HBV or HBx. Ra-
ther, those investigators observed that HBx interacted
with PI3KC3 and enhanced the latter’s activity [88].
HBV can also induce autophagy indirectly via the in-
duction of cellular stress [94-96] (Figure 2). In searching
for the mechanism leading to autophagy upon HBV ex-
pression, Li and collaborators found that the expression
of HBV small surface protein (SHBs) induced ER stress
and subsequently the activation of three signaling path-
ways PERK, ATF6 and IRE1. They further demonstrated
that the blockade of any of these three UPR (unfolded
protein response) signaling pathways blocked autophagy
induction. Their study supports the idea that induction
of ER stress by SHBs is the inducer of autophagy [87].
Moreover, the authors observed an interaction between
SHBs proteins and the autophagosome marker LC3, sug-
gesting that this interaction could be involved in the
enveloping process of HBV virions (Figure 2). How
autophagy enhances viral envelope acquisition needs fur-
ther investigation. One should note that another group
has reported findings in contradiction with the notion
that SHBs proteins increase autophagy without enhan-
cing the rate of protein degradation or that autophagy
favors virus replication. Indeed, Lazar and collaborators
showed that HBV activates UPR through the increase of
EDEM1 expression, which negatively controls viral par-
ticle production [97]. They demonstrated that EDEM1
expression leads to the degradation of HBV envelope
proteins L, M and S by autophagy. However, Lazar and
coworkers studied the role of EDEM1 on viral surface
protein stability in HEK293T cells that over-expressed
viral envelope proteins. Whether envelope proteins are
degraded in the setting of authentic HBV infection and
replication was not addressed.Lessons learned from human retroviruses
Human immunodeficiency virus-1 (HIV-1) is the causa-
tive agent for acquired immunodeficiency syndrome
(AIDS) [98,99]; the virus infects over 30 million indivi-
duals worldwide and causes approximately 3 million
deaths each year. HIV-1 infects and replicates in CD4+
T cells and macrophages [100,101]. After entry into cells,
HIV-1 replication is challenged by cellular autophagic
degradation [102] and/or by host cell restriction factors
[103-105], such as APOBEC3G [106,107], BST-2/
Tetherin [108-110], TRIM5α [111,112], SAMHD1 [113-
116], and microRNAs [117,118]. However, HIV-1 has
evolved means to counter these defense mechanisms to
overcome these cellular restrictions. For example, HIV-1
uses viral accessory protein Vif to promote the degrada-
tion or exclude the virion incorporation of APOBEC3G
[106,119]; the Vpu protein to counter the effect of BST-
2/Tetherin [109,120,121], and the Tat protein to modu-
late cellular miRNA activity [122,123].
Regarding autophagy, HIV-1 apparently subverts this
cellular defense process in a manner to benefit viral repli-
cation. In macrophages, the viral accessory protein Nef
[124,125], by interacting with Beclin-1, has been found to
block the maturation step of autophagy and thus acts to
prevent the destruction of HIV-1 [126] (Figure 3A). Treat-
ment of BFA, an inhibitor of autophagosome-lysosome fu-
sion, enhances accordingly HIV-1 production [127].
Additionally, immunity-associated GTPase family M
(IRGM), which interacts with Atg5 and Atg10, has been
reported to be another target of Nef for the accumulation
of autophagosomes and HIV-1 production [80]. It has
been observed that a Nef-deficient HIV-1 cannot over-
come autophagic degradation and replicates less efficiently
[126]. Overall, the current findings are that the early steps
of autophagy contributes to HIV-1 replication (Figure 3A),
and consistent with this notion, HIV-1 Gag is seen coloca-
lized with LC3-enriched autophagosomes; and treatment
of cells with the autophagy inhibitor 3-methyladenine (3-
MA) and siRNA-mediated knockdown of Beclin-1 or
Atg7 significantly reduces the yield of HIV-1, while the
autophagy inducer rapamycin enhances virus production
[126]. A recent study also found that vitamin D treatment
can inhibit HIV-1 replication through initiating and pro-
moting the maturation of autophagy, and that treatment
of cells with BFA and knockdown of Beclin-1 and Atg5
counter the inhibitory effect of vitamin D [128]. These
results suggest approaches that increase autophagosome-
lysosome fusion could potentially be useful anti-HIV-1
therapeutic strategies.
HIV-1 infection of CD4+ T cells is not identical to its
infection of macrophages. Unlike reports from macro-
phages, HIV-1 infection in MOLT-4 T lymphoblast cell
line and CD4+ T cells has been suggested by one re-
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Figure 3 Human retroviruses subvert autophagy. (A) HIV-1 infection of macrophages induces autophagy to enhance viral replication.
Inhibition of autophagy by 3-MA, Beclin-1 siRNA, Atg7 siRNA and vitamin D has been demonstrated to reduce HIV-1 replication [125,126,128].
Additionally, HIV-1 Nef protein inhibits autophagic clearance of HIV-1 by blocking the autophagosome-lysosome fusion; treatment of vitamin D
overcomes this blocking to enhance HIV-1 clearance [128]. (B) The autophagic effect of HIV-1 infection in CD4+ T cells is still controversial. Espert
et al. and Zhou et al. observed that HIV-1-infected CD4+ T cells exhibits reduced autophagy [127,129]. However, Wang et al. reported that HIV-1
infection of CD4+ T cells activates autophagy and that treatment of autophagy inhibitor 3-MA and Beclin-1 siRNA suppresses HIV-1 replication
[131]. Eekels et al. performed shRNA-mediated stable knockdown of autophagy-related genes (such as Atg5 and Atg16) and showed an inhibitory
effect on HIV-1 production [132]. In uninfected bystander CD4+ T cells, circulating HIV-1 env protein activates autophagy to cause apoptotic cell
death, which can be inhibited by treatment of 3-MA and BFA or Beclin-1 siRNA and Atg7 siRNA [127,133,134]. (C) HTLV-1-infected T cells exhibit
an increase of autophagy for its survival and viral replication [147] (Tang et al., submitted). Genetic disruption of Beclin-1 reduces the viability of
HTLV-1-transformed T cells [147], and BFA treatment enhances HTLV-1 replication (Tang et al., submitted). HTLV-2 Tax-immortalized CD4+ T cells
show increased autophagy, which is essential for its survival. Autophagy inhibitors 3-MA and chloroquine suppress the proliferation and induce
the apoptosis of HTLV-2 Tax-immortalized T cells [148].
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this indicates that in T-cells the process of autophagy
may be a net negative for HIV-1 replication [130]. How-
ever, this notion is somewhat unsettled because another
group has reported that autophagy is induced by HIV-1
infection of CD4+ T cells, as shown by increased levels
of Beclin-1 and LC3 [131] (Figure 3B). Moreover, they
found that the levels of ULK1, Atg4D, Atg5 and Atg12
conjugates were also increased by HIV-1 or HIV-2 infec-
tion, and that autophagy inhibitor 3-MA and Beclin-1
siRNA were able to inhibit HIV-1 replication in Jurkat T
cells [131]. Elsewhere, the stable knockdown of
autophagy-related genes, such as Atg5 and Atg16 also
was seen to inhibit HIV-1 production in SupT1 cells
[132]. These results suggest that activation of autophagy
is a net positive for HIV-1 in T cells; indeed, the rela-
tionship between HIV-1 and autophagy in T-cells
remains incompletely understood and requires further
investigation.Further complicating the picture is a postulated role of
HIV-1 on the autophagy status of uninfected bystander
CD4+ T cells. Through interacting with CXCR4 or
CCR5, soluble circulating HIV-1 env protein induces
autophagy to trigger apoptosis in uninfected CD4+ T
cells (Figure 3B), accounting in part for the clinical de-
pletion of CD4+ T cells [127,133,134]. The apoptotic cell
death induced by env protein can be fully inhibited by
treating cells with 3-MA and BFA, or using siRNAs to
knock down Beclin-1 and Atg7, indicating a link be-
tween autophagy and apoptosis through autophagy-
related proteins [130,133].
Another human retrovirus is the Human T-cell
Leukemia Virus type 1 (HTLV-1), which was identified a
few years prior to HIV-1, and is the etiological agent for
a human lymphoproliferative malignancy, adult T-cell
leukemia (ATL), and chronic inflammatory diseases, in-
cluding HTLV-1-associated myelopathy (HAM)/tropical
spastic paraparesis (TSP) [135-138]. HTLV-1 infects
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[139]. The virus infects CD4+ T cells, CD8+ T cells, B
cells, macrophages and fibroblasts; this diversity of infec-
tion occurs possibly because of the ubiquitous distribu-
tion of its hypothesized receptors (glucose transporter 1,
heparan sulfate and proteoglycans and neuropilin-1)
[140,141]. Empirically, HTLV-1 primarily targets CD4+
T cells, resulting in persistent NF-κB activation by the
viral regulatory protein Tax, leading to the clonal expan-
sion of CD4+ T cells [142-146].
A recent report showed that HTLV-1-infected T cells
exhibit increased autophagy and that the genetic disrup-
tion of Beclin-1 decreased the viability of HTLV-1-
transformed T cells [147] (Figure 3C). HTLV-1 Tax was
found to interact with the Vps34-Beclin1 complex in
IKKβ –dependent fashion [147]. Additionally, HTLV-1
infection and Tax expression have been found to induce
autophagy; and in this setting, blocking the
autophagosome-lysosome fusion was shown to benefit
virus replication (Tang et al., submitted) (Figure 3C).
Mechanistically, the ability of HTLV-1 Tax to activate
NF-κB pathway correlates with its induction of autopha-
gosome accumulation (Tang et al., submitted).
Separately, it has been reported that CD4+ T cells
immortalized by HTLV-2 Tax protein have increased LC3-
II compared to Jurkat T cells, and that autophagy inhibi-
tors (3-MA and chloroquine) inhibit the proliferation and
induce the apoptosis of HTLV-2 Tax-immortalized T cells
[148] (Figure 3C). HTLV-2 Tax was shown to interact with
Vps34, IKKβ and Beclin-1, and shRNA-mediated knock-
down of IKKβ or Beclin-1 expression reduced HTLV-2
Tax-induced accumulation of LC3-II, providing a possible
mechanism for how HTLV-2 Tax activates autophagy
[148]. Going forward, a comparison of similar/different
mechanism(s) shared by HTLV-1 and −2 Tax proteins in
autophagy induction would be informative.
A recent study suggested that the degradation of IKK
(inhibitor of kappa B kinase) induced by geldanamycin
inhibition of Hsp90 (heat shock protein 90) is through
the autophagy, not the proteasome, pathway. In Atg5-
deficienct cells with impaired autophagy, IKK degrada-
tion induced by geldanamycin treatment is attenuated,
indicating that in this setting, autophagy plays a key role
[149]. Additionally, treatment with autophagy inhibitors
increased the survival of ATL cells when their Hsp90 pro-
tein is inhibited by geldanamycin treatment [150,151].
These results implicate autophagy as playing a physio-
logical role in the death of ATL cells.
Conclusions
Autophagy is a highly conserved process used to regulate
cellular metabolism and to protect cells against invading
pathogens. Accumulating findings have, however, suggested
that many pathogens have evolved countermeasures toovercome the cell’s autophagic defense. Currently, a few
bacteria strains and many virus types have adopted means
to evade and usurp the autophagic process. Indeed, the
ability to block autophagosome-lysosome fusion seems to
be a common mechanism used by many viruses to induce
autophagosome membrane generation; these viruses have
evolved mechanisms to interrupt autophagosome destruc-
tion by preventing its fusion with lysosome. A number of
viruses have adapted to utilize autophagosome membranes
for the efficient replication of their viral genomes. As we in-
creasingly understand virus-cell interaction, it appears that
pharmaceutical agents that enhance autophagosome-
lysosome fusion might be useful clinical tools. Recently,
Campbell et al. found a promoting effect of vitamin D on
autophagosome-lysosome fusion [128], raising the pos-
sible use of vitamin D in the clinical treatment of
autophagy-related diseases, such as virus infection, can-
cers, and protein aggregate-related neurodegenerative
diseases. The discovery of additional useful autophagy in-
ducing and inhibiting molecules promises to be an exciting
and fruitful area for future research.
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